



Oxford Cannabinoid Technologies Holdings plc

Management Team

Clarissa Sowemimo-Coker – Chief Executive Officer

Clarissa was confirmed as Chief Executive Officer in April 2023 having been appointed on an interim basis in December 2022.

Clarissa joined the Group's executive team in December 2018 as General Counsel and Company Secretary, with responsibility for all legal aspects of the business as well as compliance, regulation, diversity and inclusion, people, culture and communications. She was appointed to the Group's Board in February 2021 as Chief Operating Officer, taking responsibility for the operational side of the Group in addition to inputting on the Company's strategic goals. Clarissa was instrumental in the Group's listing on the Main Market of the London Stock Exchange in May 2021.

Clarissa worked for many years as a solicitor and commercial consultant to companies in the retail, telecoms, and pharmaceutical sectors. Following an early career with Penningtons Manches Cooper LLP in London, where she spent time seconded to a range of clients including London Underground Limited and All Saints Retail Limited, she held posts as senior in-house counsel in established corporations including Hutchison 3G UK Limited (Three) and Virgin Media Limited, a subsidiary of Liberty Global plc. She is a qualified solicitor in England and Wales a member of ICSA, The Chartered Governance Institute. Clarissa is also a management coach and has delivered compliance training and management coaching to blue chip clients including Google LLC, Biogen Inc. and McDonald's Corporation across the EMEA and APAC regions.

Clarissa holds a BA in philosophy and literature from Warwick University and PGDL and LPC from BPP Law School in London. After completing her undergraduate degree, Clarissa spent two years working as a project manager in the residential construction industry before retraining as a solicitor. She is a Legal Geek mentor and an elected member of the Parochial Church Council of St John the Evangelist, Notting Hill.

Dr Valentino Parravicini – Chief Scientific Officer

Dr Valentino Parravicini joined the Group as Chief Scientific Officer in July 2020. He is responsible for the designing, planning and delivering of the scientific strategies in alignment with corporate objectives set by the Board.

Valentino has over 10 years of experience in drug discovery and development accrued while working in Big Pharma and SMEs. He started his research and development career as a scientist at Roche S.p.A in Italy, before joining GlaxoSmithKline plc in the UK as investigator in the Epigenetic Drug Performance Unit of the Immune- Inflammation Therapeutic Area. He was also involved in setting up

two start-up biotechnology companies at Kesios Therapeutics Limited and at GammaDelta Therapeutics Ltd.

Before joining the pharmaceutical industry, Valentino had an academic career at the National Institute of Arthritis and Musculoskeletal and Skin Diseases at the National Institute of Health (USA) and at the National Institute for Medical Research – Medical Research Council, Mill Hill, now part of the Francis Crick Institute (UK), where his research in inflammation and autoimmunity led to the discovery of a previously unknown signalling pathway.

He has lead research teams and programmes in the fields of immune-inflammation, oncology, and virology, both in small molecules and cell therapy. He has acquired a wide breadth of knowledge in *in vitro* and *in vivo* models in drug discovery research and development and has many high impact publications to his name.

Valentino holds a Doctoral Degree in Medicinal Chemistry from the University of Milan (Italy), where he also obtained the professional qualification of pharmacist. He has PRINCE2 accreditation in project management and he obtained a Home Office Personal Licence (PIL-AB). He became a Fogarty Fellow at the National Institute of Health, and, as part of his national service, he worked in a non-governmental organisation to support education, prevention and treatment of cancer.

Dr Tim Corn – Chief Medical Officer

Dr Tim Corn joining the Company in June 2023. He will oversee the Company's clinical research and development activities as well as providing expert medical guidance and advice to the team.

Tim is an independent pharmaceuticals consultant who has held senior positions in both large and small pharma organisations. He is currently CMO at Nodenza Inc and Medical Adviser to Confo Therapeutics SA, which recently announced a global licensing deal with Eli Lilly and Company for the clinical stage peripheral pain candidate CFTX-1554 and back-up compounds. He also serves as a non-executive director on the Board of Physiomics plc.

He was formerly Chief Medical Officer International at Jazz Pharmaceuticals plc and CMO at venture-backed companies EUSA Pharma Inc, acquired by Jazz Pharmaceuticals plc in 2012, and Zeneus Pharma Ltd. Tim has also played a key role in the successful conclusion of more than twenty regulatory approvals in the US and Europe. and is the author of more than forty scientific publications.

Tim qualified in medicine at King's College Hospital, London. After gaining a master's degree in biochemistry from Imperial College, he became consultant and senior lecturer in neuropsychiatry at the Institute of Psychiatry, London. He has been elected a Fellow of both the Faculty of Pharmaceutical Medicine and the Royal College of Psychiatrists and is the author of more than forty scientific publications.

Paul Smalley – Finance Director

Paul joined the Company from Panthera Biopartners Ltd (date), a clinical trials management company where he was Finance Director and Company Secretary overseeing financial and treasury management, as well as assisting with mergers and acquisitions.

Paul is a CIMA qualified accountant, with more than 25 years' UK and international financial experience including strategic management capabilities gained across a wide range of market sectors, with expertise extending to IT, HR and procurement. He has worked in a variety of

organisations, from SMEs to quoted companies including as Finance Director of JOST UK Ltd, which was a UK subsidiary of JOST Werke AG, a company quoted on the Frankfurt Stock Exchange.

Paul holds a BA in Accounting and Finance from Lancaster University and is also a chartered global management accountant.

Rob Bennett – General Counsel and Company Secretary

Rob Bennett joined the Company as General Counsel in December 2022 and was appointed Company Secretary in January 2023. With ultimate responsibility for all legal aspects of the business, as well as compliance and regulation, he provides guidance to the other members of the Executive Team and Board of Directors on matters related to corporate governance and risk management. He brings over 15 years of experience in legal, risk, and compliance gained through working with SMEs and quoted companies, most recently as General Counsel and Company Secretary of Bestway Retail (formerly Costcutter Supermarkets Group). Throughout his career, he has executed a diverse portfolio of M&A transactions valued at over \$10 billion across multiple countries. He has been recognised for his work, listed in Legal 500's GC Powerlists in 2021 and 2022, and as a Team of the Year finalist at The Lawyer Awards in 2021.

Rob holds a BEng (Hons) in Electronic Engineering and Business Management from the University of York and PGDL and LPC from The College of Law (now University of Law), York. After a decade in the law, he spent three years working in Corporate Finance and Development before returning to the legal field. Aside from his professional responsibilities, Rob serves as a trustee (Chair of the Finance and Audit Committee) of South Bank Multi-Academy Trust, as well as coaching youth football.

To find out further information or to see the Company presentation please visit the Company website at www.oxcantech.com

ENDS

Press pack Management Team biographies posted 27 July 2023